Summary of Conference Call Records Industry Overview - The life sciences service sector, particularly the CXO segment, continues to experience high growth and is expected to deliver strong performance in 2026, benefiting from the upward cycle in innovative drugs and improved investment conditions [1][2][3] Key Companies and Performance - Notable companies in the life sciences service industry include: - **Hao Yuan Medicine**: Q3 revenue growth close to 30%, with a non-recurring profit growth of 70%. The company has secured orders exceeding 630 million yuan, a 50% year-on-year increase [2][8] - **Bai Ao Sai Tu**: Achieved a revenue growth of 60% in Q3 and recorded its first annual profit, with significant potential in humanized mouse sales and antibody business [2][8] - **WuXi AppTec**: Expected to see over 60% revenue growth in the ADC sector in the first half of 2026, with a strong order backlog [10][19] - **Kailai Ying**: Positioned well in the ADC market, with significant growth potential [10][19] - **Yangguang Nuohe**: Anticipated to achieve a profit of 300 million yuan in 2026, with a promising drug pipeline [20] Financial Performance - In the first three quarters of 2025, 16 representative life sciences service companies reported revenue and profit growth rates of high single digits and double digits, respectively. In Q3 alone, revenue and profit growth rates were double digits and 50%, indicating significant operational improvement [4][6] - The gross profit margin is expected to improve due to a clearer competitive landscape, leading to enhanced industry profitability [4] Market Trends - The overseas market is benefiting from improved investment conditions and the Federal Reserve's interest rate cuts, leading to an increase in the share of overseas business and expanding global market potential [7] - The domestic CRO market is experiencing a price recovery trend after years of intense competition, with expectations for more significant price improvements by 2027 as supply conditions stabilize [11][12] Growth Opportunities - The ADC and small nucleic acid sectors are projected to bring substantial order increases in 2026, with companies like WuXi AppTec and Hao Yuan Medicine expected to lead this growth [10][19] - The CRO sector is seeing a shift towards innovation, with companies like Yangguang Nuohe and Chengdu Xian Dao making progress in developing innovative drugs [13] Investment Recommendations - Recommended companies for investment include: - **WuXi AppTec**: Strong growth in peptide business and expected to achieve significant revenue increases [14][17] - **Kailai Ying**: Leading in peptide capacity expansion [14] - **Tigermed**: Positioned well in the CRO market with growth potential [21] - **Norseg and Prasis**: Expected to benefit from overall industry trends [17] Conclusion - The life sciences service industry is poised for continued growth, driven by innovative drug development, improved investment conditions, and a recovering market landscape. Key players are expected to deliver strong financial performance, making them attractive investment opportunities.

Group 1 - The report maintains an optimistic outlook for the convertible bond market in January 2026, driven by policy expectations and seasonal capital inflows, which are expected to create a "good start" for the market [6][17] - The central economic work conference has identified "technological innovation" and "expanding domestic demand" as key policy focuses, with related industry policy benefits expected to continue, directly boosting market risk appetite [6][17] - The convertible bond market is experiencing a tight supply-demand balance, with the total size of publicly traded convertible bonds at approximately 527.1 billion yuan as of December 31, 2025, down 183.6 billion yuan from the beginning of 2025 [19] Group 2 - The report suggests focusing on growth styles in investment strategies, particularly in technology sectors such as aerospace, AI computing, semiconductor equipment, and innovative pharmaceuticals, which are expected to benefit from industry policy support [6][20] - The top ten convertible bond portfolio for January 2026 emphasizes aggressive and elastic sectors, with a focus on technology growth, cyclical recovery, and financial sectors [6][20] - Specific recommendations include increasing holdings in convertible bonds from companies like Yinbang, Zhenhua, and Yingliu in the technology sector, and focusing on cyclical sectors such as precious metals and chemicals [20][22]

Core Viewpoint - The article discusses the performance of the Zhongzheng 1000 ETF Enhanced (561280), highlighting its opening price and the performance of its major holdings since its inception on August 31, 2023, which has yielded a return of 57.53% [1]. Group 1: ETF Performance - The Zhongzheng 1000 ETF Enhanced (561280) opened at 1.578 yuan, experiencing a decline of 0.19% [1]. - Since its establishment on August 31, 2023, the fund has achieved a return of 57.53% [1]. - The fund's performance over the past month has been a return of 6.26% [1]. Group 2: Major Holdings - Major stocks in the fund include: - Boqian New Materials, which opened with an increase of 0.68% [1]. - Haoyuan Pharmaceutical, which rose by 0.78% [1]. - Yingjixin, which increased by 0.56% [1]. - Caixun Co., which saw a slight increase of 0.08% [1]. - Jinma Leisure, which rose by 0.41% [1]. - Panjiang Co., which remained unchanged [1]. - Jindawei, which decreased by 0.10% [1]. - Yiyuan Communication, which increased by 0.43% [1]. - Minxin Co., which remained unchanged [1]. - Nami Technology, which rose by 0.34% [1]. [1]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2026-001 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 累计转股情况：上海皓元医药股份有限公司（以下简称"公司"）向不 特定对象发行可转换公司债券"皓元转债"自 2025 年 6 月 4 日开始转股。截至 2025 年 12 月 31 日，累计已有人民币 491,000 元"皓元转债"转换为公司股票， 累计转股数量为 12,077 股，占"皓元转债"转股前公司已发行股份总额的 0.0057%。 未转股可转债情况：截至 2025 年 12 月 31 日，"皓元转债"尚未转股的 金额为 821,859,000 元，占"皓元转债"发行总量的 99.94%。 本季度转股情况：自 2025 年 10 月 1 日至 2025 年 12 月 31 日期间，"皓 元转债"共有人民币 27,000 元转换为公司股票，转股数量为 665 股，占"皓元 转债"转股前公司已发行股份总额的 0.0003%。 一、可转债发行上市概况 可转债转股结果暨股份变动公告 本公司董事会及全体 ...

Investment Rating - The industry investment rating is "Overweight" [2] Core Insights - Antibody-drug conjugates (ADCs) have become one of the most promising and fastest-growing treatment methods, combining the precise targeting characteristics of antibody drugs with the strong cytotoxicity of small molecule drugs. ADCs show better clinical trial results compared to traditional chemotherapy, which has high off-target toxicity and increased risk of infection. The ADC market is expected to enter an explosive growth phase, with projections indicating a global market size of $115.1 billion by 2032 [5][22][68]. Summary by Sections ADC Drug Development - ADCs are characterized by their core components: highly effective cytotoxic drugs, specific monoclonal antibodies, and linkers that connect the two. The development of ADCs has made significant progress, with the first ADC approved by the FDA in 2000. The market for ADCs has grown rapidly from $2 billion in 2018 to $10.4 billion in 2023, with a CAGR of 38.6% [15][22]. ADC Industry Outlook - The ADC industry is experiencing high demand for outsourcing services, with an outsourcing rate of approximately 70%, significantly higher than the 34% for traditional biopharmaceuticals. The global ADC CXO market is projected to reach $11 billion by 2030, with a CAGR of 28.4% from 2022 to 2030 [6][31][69]. Key Companies - **WuXi AppTec**: A leading global CRDMO company in bioconjugates, with rapid revenue growth from $0.096 billion in 2020 to $4.052 billion in 2024, and a projected capital expenditure exceeding 7 billion RMB by 2029 [7][39]. - **Hao Yuan Medicine**: Focused on ADC development for over a decade, with over 90 ADC projects and more than 1,200 clients. The company has established a comprehensive ADC CDMO platform and is expanding its production capacity [7][53]. - **Easton Pharmaceuticals**: Provides a full range of CDMO services for ADCs and has supported multiple projects, including the first dual-load ADC project approved for clinical trials [8][61]. - **Kelaiying**: A leading CDMO that has entered the biopharmaceutical sector, with significant growth in ADC-related business and ongoing expansion of production capacity [9][64].

证券日报网讯 12月29日，皓元医药在互动平台回答投资者提问时表示，公司始终坚持产业化、全球化 发展战略，已在国内外建设多个仓储中心，在美国设立仓储和商务团队，运用国际化运营及管理方式有 效整合公司资源，建立覆盖全球的网络销售平台，提供直观便捷的购买渠道，快速响应和满足客户需 求。公司前端业务包含分子砌块、工具化合物等生命科学试剂产品，该类产品具有标准化、小批量、高 频次的交付特点，适配快速配送需求。同时通过数字化管理系统建立智能备货机制，优化订单处理流 程，实现工作日下单快速响应，为次日送达提供技术保障。 ...

Investment Rating - The report maintains an "Outperform" rating for several companies in the pharmaceutical sector, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with promising pipelines and performance growth in the Biopharma/Biotech sector, maintaining an "Outperform" rating for Innovent Biologics, WuXi XDC Cayman, and others [5][23]. - It highlights the performance of the A-Shares pharmaceutical sector, which underperformed the market, with the SW Pharma & Bio index falling by 0.2% while the SHCOMP rose by 1.9% [7][18]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level of 66.7% as of December 26, 2025 [13][17]. Summary by Sections 1. Continued Recommendation for Innovative Drugs and Industry Chain - The report continues to recommend innovative drugs and the associated industry chain, highlighting the high demand and potential for revaluation in the pharmaceutical sector [5][23]. - Specific companies recommended include Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical, all rated as "Outperform" [5][6]. 2. A-Shares Pharmaceutical Sector Performance - In the fourth week of December 2025, the A-Shares pharmaceutical sector underperformed the broader market, with a decline of 0.2% compared to a 1.9% increase in the SHCOMP index [7][18]. - The best-performing sub-sectors included chemical raw materials (+2.0%) and medical equipment (+0.1%), while biological products saw a slight decline of -0.1% [9][18]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Biotechnology index down by 2.3% [18]. - In contrast, the U.S. pharmaceutical sector performed similarly to the market, with the S&P Healthcare Select Sector increasing by 1.0% [18].

（文章来源：证券日报） 证券日报网讯 12月26日，皓元医药发布公告称，2025年12月26日，苏信基金通过集中竞价减持皓元医 药546405股，占总股本0.26%，减持价格71.00元/股至73.15元/股，减持总金额39278669.66元，减持后不 再持股。 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-131 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，上海皓元医药股份有限公司（以下简称"公司"）股 东苏民投君信（上海）产业升级与科技创新股权投资合伙企业（有限合伙）（以 下简称"苏信基金"）持有公司 546,405 股股份，占减持计划实施前公司总股本 的 0.26%。上述股份为公司首次公开发行前及上市后权益分派资本公积转增股本 取得的股份，并已上市流通。 减持计划的实施结果情况 公司于 2025 年 12 月 22 日在上海证券交易所网站（www.sse.com.cn）披露 了《上海皓元医药股份有限公司股东减持股份计划公告》（公告编号：2025-130）。 苏信基金拟通过集中竞价的方式减持不超过 546,405 股公司股份，拟减持比例不 超过减持计划实 ...

从资金流向上来看，当日医疗服务板块主力资金净流出8.24亿元，游资资金净流入4129.99万元，散户资 金净流入7.83亿元。医疗服务板块个股资金流向见下表： 证券之星消息，12月26日医疗服务板块较上一交易日下跌0.21%，皓元医药领跌。当日上证指数报收于 3963.68，上涨0.1%。深证成指报收于13603.89，上涨0.54%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600721 | 自花医药 | 12.24 | 5.88% | 48.95万 | | 5.94亿 | | 301096 | 百诚医药 | 55.93 | 3.79% | 5.12万 | | 2.84亿 | | 000504 | *ST生物 | 9.20 | 3.25% | 2.70万 | | 2461.38万 | | 301201 | 诚达药业 | 41.95 | 0.84% | 6.37万 | | 2.72亿 | | 603259 | 药明康德 | 92.70 | 0. ...